Exendin 4


  • Description

  • Application Data


Exendin-4 is an incretin mimetic that stimulates insulin secretion, an analogue of GLP-1 but resistant to cleavage by plasma DPP-IV.

See full description

Application Data

Catalogue number crb1000146
Molecular Weight 4186.63
Sequence (one letter code)


Sequence (three letter code)


Purity >95%
Storage This material should be stored below 0 degrees C

Kolterman et al., (2005). Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am. J. Health Syst. Pharm., 62: 173. PMID: 15700891.

Liao et al., (2015). In Vitro Metabolic Stability of Exendin-4: Pharmacokinetics and Identification of Cleavage Products. PLOS ONE, 10(2): e0116805. PMID: 25723538. 


Material Safety Data Sheet (MSDS)

Originally identified in Gila monster lizard (Heloderma suspectum), exendin-4 is an incretin mimetic, an analog of glucagon-like-peptide-1 (GLP-1), it stimulates insulin secretion and modulates gastric emptying to slow the entry of ingested sugars into the bloodstream. Exendin-4 is resistant to cleavage by plasma DPP-IV unlike GLP-1. This gives it a longer half-life and duration of action than GLP-1, as well as greater potency in vivo. Exendin-4 increases insulin sensitivity and improves glucose tolerance and is currently used for the treatment of Type 2 diabetes mellitus in its synthetic form Exenatide.

Exendin-4 also promotes the production and proliferation of β-cells leading to regeneration of the pancreas. It is a ligand to the exendin receptor and increases pancreatic acinni cAMP levels. However, the GLP-1 analog was found to have a toxic effect by inducing hypotension due to relaxation of the cardiac smooth muscle.

Exendin 4

Cat No.Pack SizePriceQty.
Bulk Quote

Download Family PDF

You may also like…